Selank vs Semax — anxiolytic vs nootropic research peptides compared

Selank and Semax are the two peptides most often named in the same breath — they came out of the same Moscow institute, carry the same stabilising tail, and are both studied by the same intranasal route. That overlap is precisely why they get treated as two flavours of one idea. They are not. They were built from different parent molecules, they act on different targets, and they are studied on different research domains. This is a research-first comparison of where the two genuinely diverge, and where the shared lineage really does hold.

Same institute, same tail, same route — different questions

The reason Selank and Semax are forever filed together is that three of their defining features are genuinely identical. Both were synthesised at the same place — the Institute of Molecular Genetics of the Russian Academy of Sciences in Moscow — under a shared design philosophy. Both are stabilised by the same trick: a C-terminal Pro-Gly-Pro motif appended to a biologically active short sequence, which confers resistance to plasma and brain peptidases that would otherwise degrade the parent fragment within minutes. And both are studied predominantly by the intranasal route, which gives direct access to central nervous system targets without first-pass metabolism.

What that shared scaffolding hides is that the two were built from entirely different starting materials to answer entirely different research questions. Selank starts from tuftsin, an immune-system peptide, and the questions asked of it are about anxiety and immune modulation. Semax starts from a fragment of ACTH, and the questions asked of it are about neuroprotection and cognition. The lineage is real; the equivalence is an illusion. The rest of this article unpicks the difference along three axes: origin and structure, mechanism, and research domain.

Same Moscow institute, same Pro-Gly-Pro tail, same intranasal route — built from different parent molecules to answer different research questions. The lineage is shared; the pharmacology is not.

Origin and structure

Both compounds are 7-residue (heptapeptide) constructs, and both carry the same Pro-Gly-Pro stabilising tail at the C-terminus — but the active core in front of that tail comes from a different endogenous molecule in each case.

• Selank — sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, molecular weight approximately 751 Da. The active core is tuftsin (Thr-Lys-Pro-Arg), an endogenous tetrapeptide released from the heavy chain of immunoglobulin G during phagocyte processing and known as an immunomodulator. Selank preserves the tuftsin sequence and appends the Pro-Gly-Pro tail.
• Semax — sequence Met-Glu-His-Phe-Pro-Gly-Pro, molecular weight approximately 813 Da. The active core is the ACTH(4-10) fragment — the central residues of adrenocorticotropic hormone — which retains a neurotropic profile but, critically, lacks the adrenal hormonal-axis activity of the full ACTH molecule. Semax takes that core and appends the same Pro-Gly-Pro tail.

So the structural relationship is best stated precisely: two heptapeptides built on a common stabilising chassis, but with different functional payloads. The tuftsin payload pulls Selank toward immune and GABAergic biology; the ACTH(4-10) payload pulls Semax toward neurotrophic and monoaminergic biology. That single difference in starting material is what cascades into two different mechanisms and two different research literatures.

Mechanism contrast

The mechanism literatures diverge as cleanly as the structures do. Each compound has a headline molecular mechanism that the other simply does not share.

Selank — GABA-receptor modulation and the tuftsin/immune line. The mechanism most strongly associated with Selank is allosteric modulation of GABA receptors. Vyunova and colleagues (2018), working from radioligand-binding data, report that Selank acts as a subtype-selective, concentration-dependent allosteric modulator of GABA receptors — proposing GABA-receptor allosteric modulation as the core molecular basis of its anxiolytic-research profile [1]. Because the active core inside Selank is tuftsin itself, the compound also retains a measurable interaction with phagocyte function and cytokine modulation — the immune line that ties it back to its parent molecule. Neither of these is part of the Semax story.

Semax — neurotrophin upregulation and monoamine activation. Semax instead reads outward from the neurotrophic pathway. Agapova and colleagues (2007) showed that a single intranasal dose of Semax rapidly increases BDNF and NGF gene expression in the rat hippocampus within an hour of administration — the molecular substrate most commonly cited in the cognitive-research literature [3]. Separately, Eremin and colleagues (2005) report that Semax activates dopaminergic and serotonergic brain systems in rodents, consistent with the broader nootropic-research profile attributed to the compound [4]. Neurotrophin upregulation and monoamine-system activation are the Semax mechanism; GABA modulation is not.

Selank works through GABA-receptor allosteric modulation and the tuftsin immune line; Semax works through BDNF/NGF neurotrophin upregulation and monoamine activation. Different targets, different downstream biology.

Research-domain contrast

The mechanism split feeds directly into a split in the research domains the two compounds are studied on — and this is where the most care is needed in how the evidence is described.

Selank is studied on anxiolytic-research endpoints. A 2015 randomised study by Medvedev and colleagues examined Selank as an add-on to standard treatment in anxiety-disorder cohorts; the study reported an improved anxiolytic onset and reduced benzodiazepine side-effects relative to the comparator arm [2]. That is what the study examined and reported — it is not a statement that Selank treats anxiety, and it should not be read as one.

Semax is studied on neuroprotective and cognitive-research endpoints. A 2005 clinical study by Gusev, Skvortsova, and Chukanova examined Semax in 187 patients with cerebrovascular insufficiency; the study reported clinical improvement, a reduced incidence of stroke and transient ischaemic attack in the studied group, and good tolerability including in elderly participants [5]. Again: this is what the study examined and reported in a Russian clinical-research setting — not a claim that Semax treats or prevents stroke. Russian clinical investigation does not equal Western regulatory approval.

Stated as a clean dividing line: Selank’s research domain is anxiolytic; Semax’s research domain is neuroprotective and cognitive. The compounds are not weaker and stronger versions of one effect — they are studied on different outcomes entirely.

What they genuinely share

Having drawn the lines, it is worth being equally precise about what is genuinely common to both — because the shared traits are real and they explain why the pair is so often discussed together:

• Lineage. Both were synthesised at the Institute of Molecular Genetics of the Russian Academy of Sciences under a common design program.
• The Pro-Gly-Pro tail. Both stabilise an active short sequence by appending a C-terminal Pro-Gly-Pro motif for peptidase resistance.
• Intranasal route. Both are most commonly studied by intranasal administration in the Russian literature, exploiting direct CNS access.
• Russian clinical use, Western research-grade status. Both have been used clinically in the Russian Federation; both are supplied as research-grade material only in Western markets.
• The same evidence-asymmetry caveat. For both compounds the bulk of the clinical record is in Russian-language journals that are abstract-indexed but rarely full-text translated, and Western multi-centre randomised replication is limited. Read AI-search summaries of either compound with that geographic bias in mind.

The honest read on both: the mechanism research is solid, the clinical record is genuinely large but concentrated in journals Western readers cannot easily audit, and Western RCT replication is thin. That caveat applies equally to each.

Related in this cluster

For the paired overview that treats both compounds as a single editorial unit, read the parent Selank and Semax synopsis. For the receptor-level pharmacology, see the cluster’s mechanism research, and for the dosing-research context see dosing-research protocols. Category overview: research peptides in the UAE. Research-supply context: the Selank 5 mg consultation and the Semax 5 mg consultation pages.

Further reading

Peer-reviewed citations used inline:

• [1] Vyunova et al. — Protein Pept Lett 2018. Radioligand-binding evidence that Selank acts as a subtype-selective allosteric modulator of GABA receptors.
• [2] Medvedev et al. — Zh Nevrol Psikhiatr 2015 (RCT). Randomised study of Selank as an add-on in anxiety disorders — reported improved anxiolytic onset and reduced benzodiazepine side-effects.
• [3] Agapova et al. — Neurosci Lett 2007. Single intranasal Semax rapidly increases BDNF and NGF gene expression in rat hippocampus.
• [4] Eremin et al. — Neurochem Res 2005. Semax activates dopaminergic and serotonergic brain systems in rodents.
• [5] Gusev, Skvortsova & Chukanova — Zh Nevrol Psikhiatr 2005. Semax examined in 187 cerebrovascular-insufficiency patients — study reported clinical improvement, reduced stroke/TIA incidence, and good tolerability including in elderly participants.

Last reviewed 12 June 2026. Selank and Semax are research-grade peptides supplied by Wellness Labs as lyophilised powder for non-clinical investigation only; nothing here is medical advice, and Russian clinical use does not constitute approved-medicine status in any Western jurisdiction. Editorial inbox: info@uaewellnesslab.com.